STEMI/NSTEMI/ACS
Moscone West, 1st Floor
Tuesday, October 29, 2013, 3:30 PM–5:30 PM
Abstract nos: 213-264

TCT-213
Everolimus-eluting stent versus bare metal stent in proximal left anterior descending ST-elevation myocardial infarction
Josep Gomez-Larí,1 Salvatore Brugaletta,2 Angel Cequier,3 Joan Antoni Gomez-Hospital,1 Manel Sabate4
1Hospital Universitari de Bellvitge, Hospital de Llobregat, Spain, 2Clinic Thorax Institute, Barcelona, Spain, 3Hospital of Bellvitge, Barcelona, Spain, 4University of Barcelona, Barcelona, Spain

Background: ST-elevation myocardial infarctions (STEMI) caused by proximal left anterior descending (LAD) lesions have more myocardial at risk and worse outcomes than those located in other segments. The aim is to compare outcomes of patients with STEMI and proximal-LAD lesions treated with bare-metal stents (BMS) versus everolimus-eluting stents (EES).

Methods: The EXAMINATION trial randomized 1498 STEMI patients to BMS vs. EES. The primary endpoint was the patient-oriented combined of all-cause death, any-recurrent myocardial infarction (MI) and any-revascularization. The secondary endpoint included the device-oriented combined of cardiac death, target-veessel MI and target-lesion revascularization (TLR).

Results: STEMI with a proximal-LAD occlusion was observed in 290 patients (BMS=132 and EES=158). Both groups were similar except for diabetes (12.9% vs. 24.1%; p=0.016). At 1 year, the primary end-point was observed in 18.9% and 9.5% of patients treated with BMS and EES, respectively (p=0.023). The secondary end-point was observed in 11.4% and 5.1%, respectively (p=0.053). There were no differences in cardiac death (4.5% vs. 3.8%; p=0.750) and MI (1.5% vs. 0%; p=0.121). BMS had higher rate of TLR compared to EES (6.8% vs. 1.3%; p=0.014). Patients with proximal-LAD STEMI had higher mortality than patients with non-proximal-LAD STEMI (5.5% vs. 2.9%; p=0.016). Proximal-LAD lesions treated with BMS tended to increase the risk of the primary end-point compared with other segments (15.9% vs. 13.0%; p=0.079). However, EES implanted in proximal-LAD had similar outcomes compared with other locations (9.5% vs. 12.0%; p=0.430). Adjusting for confounders, the interaction between BMS and proximal-LAD location was associated with the primary end-point.

Conclusions: Patients with STEMI and proximal-LAD lesions treated with EES have better outcomes compared with BMS at 1-year. Although further investigations are required, it seems reasonable to consider EES for proximal-LAD STEMI-lesions.

TCT-214
Five-year prognostic impact of distal embolization during primary percutaneous coronary intervention in ST elevation myocardial infarction patients treated with or without distal protection
Jacob T. Lamborg1, Henning Kelbaek2, Steffen Helqvist3, Lone Holmvang4, Erik Jorgensen5, Leif Kiesgaard5, Kari Saunamaki6, Klaus F. Kofod7, Lief Thuesen8, Anne Kiatof10, Christian J. Terkelsen10, Hans Erik Boeker9, Jens F. Lassen10, Lars Kobler10, Peter Clemmensen10, Thomas Engstroem10
1Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 2Rigshospitalet Copenhagen, Copenhagen, Denmark, 3Rigshospitalet, Copenhagen, Denmark, 4Department of Cardiology, Copenhagen University Hospital, Copenhagen, Copenhagen, Copenhagen, 5Department of Cardiology, University of Copenhagen, Copenhagen, Denmark, 6Department of Cardiology, Rigshospitalet, Copenhagen, Denmark, 7Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus, Denmark, 8Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus, Denmark, 9Aarhus University Hospital, Skejby, Aarhus N, Denmark, 10Aarhus University Hospital, Aarhus N, Aarhus, Denmark, 11Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus N, Denmark, 12Department of Cardiology, Copenhagen University Hospital, Copenhagen, Copenhagen

Background: The impact of angiographically visible distal embolization (DE) following primary percutaneous coronary intervention (PCI) on clinical outcome has been scarcely studied in patients with ST elevation myocardial infarction (STEMI). Moreover, the use of distal protection during primary PCI seems to improve both epicardial flow and left ventricular function, but has so far failed to impact clinical outcome. Thus, the objective of this study was to evaluate the association between (DE) and 5-year outcome in patients randomized to primary PCI with or without distal protection.

Methods: In this post-hoc study 591 STEMI patients were randomized to conventional primary PCI or primary PCI with distal protection. Primary outcome was 5-year major adverse cardiac events (all cause mortality, admission for heart failure and reinfarction).

Results: DE was observed in 8.3% of all patients. There seemed to be interaction between distal protection and DE in terms of MACCE (p=0.08), all cause mortality (p=0.02) and reinfarction (p=0.06), but no admission for heart failure (p=0.40). DE was related to increased risk of admission for heart failure independently of distal protection (12.0% versus 5.0; p=0.015). The MACCE rate was 31.3% for patients treated with standard PCI with DE compared to 24.8% for patients without DE (p=0.30), and 44.4% for patients treated with distal protection with DE compared to 17.9% for patients without DE (p=0.005). DE was not related to all cause mortality (p=0.52) or reinfarction (p=0.52) among patients treated with standard PCI, but was related to higher rates of mortality (p=0.012) and reinfarction (p=0.008) when distal protection was used.

Conclusions: The occurrence of DE during primary PCI leads to increased risk of development of heart failure. DE occurring during the use of a distal protection device aggravates the prognosis, whereas successful distal protection improves it.

TCT-215
Predictors of 1-year mortality at hospital discharge after ACS STEMI and NSTEMI: a new risk score from the EPICOR study
stuart j pocock1, L. Annemans2, H. Bueno3, Nicolas Danchin4, Muriel Licour5, Jesus Medina6, Frans Van der Wel7, Lin Zhang8
1LSHTM, London, MA, 2Department of Public Health, UGent, VUB, Ghent, Belgium, 3Hospital General Universitario Gregorio Marañón, Madrid, Spain, 4Hospital Européen Georges Pompadou, & René Descartes University, Paris, France, 5Medical Department, AstraZeneca France, Rueil-Malmaison, France, 6AstraZeneca Medical Evidence Center, Madrid, Spain, 7University Hospitals Leuven, Leuven, Belgium, 8AstraZeneca Medical Evidence Center, Wilmington, DE

Background: At hospital discharge after an ACS event, patients vary markedly in their prognosis. There is a need for a reliable prediction tool to identify patients with high mortality risk.

Methods: EPICOR (NCT01171404) is a prospective cohort study of 10568 consecutive hospital survivors after an ACS event (4943 STEMI and 5625 NSTEMI-ACS). 65.1% underwent PCI and 2.5% CABG. They were enrolled from 555 hospitals in 20 European and Latin American countries between October 2010 and March 2011. Postdischarge mortality was recorded up to 12 months. From over 50 potential predictor variables a new risk score for 1 year mortality was developed using forward Cox regression, and examined for goodness-of-fit and discriminatory power.

Results: 402 patients (3.8%) died within 1 year of discharge. We identified twelve highly significant independent predictors of mortality. In order of predictive strength they are: age, LVEF, poorer EQ-SD quality of life, elevated serum creatinine, COPD, in-hospital cardiac complications, PAD, no PCI or CABG after NSTEMI, low haemoglobin, male gender, on diuretics at discharge, elevated blood glucose. Combined into a new risk score excellent discrimination was achieved (C-statistic = 0.81). For both STEMI and NSTEMI-ACS there was a steep gradient in mortality across risk-score quintiles, with top quintile split into two deciles (see Table). One year mortality ranged from 0.5% in the lowest quintile to 18.5% in the highest decile. Note NSTEMI-ACS contributes over twice as many high-risk patients as STEMI.

Conclusions: Postdischarge mortality for ACS patients remains of concern. Our new user-friendly risk score can readily identify who is at high risk. Whether the poor prognosis of such patients can be improved warrants further study.